Thompson Michael A
From Aurora Health Care, Milwaukee, WI.
Am Soc Clin Oncol Educ Book. 2014:e101-5. doi: 10.14694/EdBook_AM.2014.34.e101.
Social media has potential in clinical trials for pointing out trial issues, addressing barriers, educating, and engaging multiple groups involved in cancer clinical research. Social media is being used in clinical trials to highlight issues such as poor accrual and barriers; educate potential participants and physicians about clinical trial options; and is a potential indirect or direct method to improve accrual. We are moving from a passive "push" of information to patients to a "pull" of patients requesting information. Patients and advocates are often driving an otherwise reluctant health care system into communication. Online patient communities are creating new information repositories. Potential clinical trial participants are using the Twittersphere and other sources to learn about potential clinical trial options. We are seeing more organized patient-centric and patient-engaged forums with the potential to crowd source to improve clinical trial accrual and design. This is an evolving process that will meet many individual, institutional, and regulatory obstacles as we move forward in a changed research landscape.
社交媒体在临床试验中具有潜力，可用于指出试验问题、解决障碍、开展教育并促使参与癌症临床研究的多个群体参与进来。社交媒体正被应用于临床试验，以突出诸如入组率低和障碍等问题；向潜在参与者和医生介绍临床试验选项；并且是提高入组率的一种潜在间接或直接方法。我们正从向患者被动“推送”信息转变为患者主动“拉取”信息。患者和倡导者常常促使原本不情愿的医疗保健系统进行沟通。在线患者社区正在创建新的信息库。潜在的临床试验参与者正在利用推特等平台及其他来源了解潜在的临床试验选项。我们看到越来越多以患者为中心且患者积极参与的有组织论坛，这些论坛有可能通过众包来改善临床试验的入组率和设计。这是一个不断发展的过程，在我们于变化了的研究格局中向前推进时，将会遇到许多个人、机构和监管方面的障碍。
